Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Oxid Med Cell Longev ; 2022: 1030238, 2022.
Article in English | MEDLINE | ID: covidwho-2194204

ABSTRACT

The effective remission of acute respiratory distress syndrome- (ARDS-) caused pulmonary fibrosis determines the recovery of lung function. Inositol can relieve lung injuries induced by ARDS. However, the mechanism of myo-inositol in the development of ARDS is unclear, which limits its use in the clinic. We explored the role and mechanism of myo-inositol in the development of ARDS by using an in vitro lipopolysaccharide- (LPS-) established alveolar epithelial cell inflammation model and an in vivo ARDS mouse model. Our results showed that inositol can alleviate the progression of pulmonary fibrosis. More significantly, we found that inositol can induce autophagy to inhibit the progression pulmonary fibrosis caused by ARDS. In order to explore the core regulators of ARDS affected by inositol, mRNA-seq sequencing was performed. Those results showed that transcription factor HIF-1α can regulate the expression of SLUG, which in turn can regulate the key gene E-Cadherin involved in cell epithelial-mesenchymal transition (EMT) as well as N-cadherin expression, and both were regulated by inositol. Our results suggest that inositol activates autophagy to inhibit EMT progression induced by the HIF-1α/SLUG signaling pathway in ARDS, and thereby alleviates pulmonary fibrosis.


Subject(s)
Pulmonary Fibrosis , Respiratory Distress Syndrome , Mice , Animals , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/chemically induced , Inositol/adverse effects , Signal Transduction , Respiratory Distress Syndrome/drug therapy , Cadherins/metabolism , Autophagy , Epithelial-Mesenchymal Transition , Lipopolysaccharides/pharmacology
2.
Structure ; 28(11): 1218-1224.e4, 2020 11 03.
Article in English | MEDLINE | ID: covidwho-872505

ABSTRACT

The ongoing global pandemic of coronavirus disease 2019 (COVID-19) resulted from the outbreak of SARS-CoV-2 in December 2019. Currently, multiple efforts are being made to rapidly develop vaccines and treatments to fight COVID-19. Current vaccine candidates use inactivated SARS-CoV-2 viruses; therefore, it is important to understand the architecture of inactivated SARS-CoV-2. We have genetically and structurally characterized ß-propiolactone-inactivated viruses from a propagated and purified clinical strain of SARS-CoV-2. We observed that the virus particles are roughly spherical or moderately pleiomorphic. Although a small fraction of prefusion spikes are found, most spikes appear nail shaped, thus resembling a postfusion state, where the S1 protein of the spike has disassociated from S2. Cryoelectron tomography and subtomogram averaging of these spikes yielded a density map that closely matches the overall structure of the SARS-CoV postfusion spike and its corresponding glycosylation site. Our findings have major implications for SARS-CoV-2 vaccine design, especially those using inactivated viruses.


Subject(s)
Betacoronavirus/ultrastructure , Disinfectants/pharmacology , Propiolactone/pharmacology , Virion/drug effects , Animals , Betacoronavirus/drug effects , Betacoronavirus/immunology , COVID-19 Vaccines , Chlorocebus aethiops , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Cryoelectron Microscopy , Electron Microscope Tomography , Humans , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/ultrastructure , Vaccines, Inactivated/immunology , Vero Cells , Viral Vaccines/immunology , Virion/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL